Omega-3 fatty acid plasma levels before and after supplementation: Correlations with mood and clinical outcomes in the omega-3 and therapy studies

L. Eugene Arnold, Andrea Young, Martha A. Belury, Rachel M. Cole, Barbara Gracious, Adina M. Seidenfeld, Hannah Wolfson, Mary A. Fristad

Research output: Contribution to journalArticle

Abstract

Objective: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. Methods: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. Results: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: The greater the EPA increase, the less the placebo-controlled Ω3 improvement. Conclusion: Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalJournal of Child and Adolescent Psychopharmacology
Volume27
Issue number3
DOIs
StatePublished - Apr 1 2017

Fingerprint

Omega-3 Fatty Acids
Eicosapentaenoic Acid
Docosahexaenoic Acids
Placebos
alpha-Linolenic Acid
Fatty Acids
Therapeutics
Depression
Blood Pressure
Linoleic Acid
Oleic Acid
Mood Disorders
Arachidonic Acid
Psychotherapy
Body Weight

Keywords

  • mediation
  • moderation
  • mood disorders
  • omega-3 fatty acids
  • plasma levels
  • supplementation as treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Omega-3 fatty acid plasma levels before and after supplementation : Correlations with mood and clinical outcomes in the omega-3 and therapy studies. / Arnold, L. Eugene; Young, Andrea; Belury, Martha A.; Cole, Rachel M.; Gracious, Barbara; Seidenfeld, Adina M.; Wolfson, Hannah; Fristad, Mary A.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 27, No. 3, 01.04.2017, p. 223-233.

Research output: Contribution to journalArticle

Arnold, L. Eugene ; Young, Andrea ; Belury, Martha A. ; Cole, Rachel M. ; Gracious, Barbara ; Seidenfeld, Adina M. ; Wolfson, Hannah ; Fristad, Mary A. / Omega-3 fatty acid plasma levels before and after supplementation : Correlations with mood and clinical outcomes in the omega-3 and therapy studies. In: Journal of Child and Adolescent Psychopharmacology. 2017 ; Vol. 27, No. 3. pp. 223-233.
@article{7e4cccd4c356447eb6784f167f06d17f,
title = "Omega-3 fatty acid plasma levels before and after supplementation: Correlations with mood and clinical outcomes in the omega-3 and therapy studies",
abstract = "Objective: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. Methods: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. Results: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: The greater the EPA increase, the less the placebo-controlled Ω3 improvement. Conclusion: Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.",
keywords = "mediation, moderation, mood disorders, omega-3 fatty acids, plasma levels, supplementation as treatment",
author = "Arnold, {L. Eugene} and Andrea Young and Belury, {Martha A.} and Cole, {Rachel M.} and Barbara Gracious and Seidenfeld, {Adina M.} and Hannah Wolfson and Fristad, {Mary A.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1089/cap.2016.0123",
language = "English (US)",
volume = "27",
pages = "223--233",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Omega-3 fatty acid plasma levels before and after supplementation

T2 - Correlations with mood and clinical outcomes in the omega-3 and therapy studies

AU - Arnold, L. Eugene

AU - Young, Andrea

AU - Belury, Martha A.

AU - Cole, Rachel M.

AU - Gracious, Barbara

AU - Seidenfeld, Adina M.

AU - Wolfson, Hannah

AU - Fristad, Mary A.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objective: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. Methods: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. Results: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: The greater the EPA increase, the less the placebo-controlled Ω3 improvement. Conclusion: Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.

AB - Objective: To examine fatty acid profiles, their response to omega-3 fatty acid (Ω3) supplementation, and associations with clinical status and treatment response in youth with mood disorders. Methods: In a placebo-controlled 2X2 design, 7-14 year-olds (N = 95) in parallel pilot trials (depression N = 72; bipolar N = 23) were randomly assigned to 12 weeks of Ω3 supplementation (1.4 g eicosapentaenoic acid [EPA], 0.2 g docosahexaenoic acid [DHA], and 0.27 g other Ω3 per day); psychoeducational psychotherapy (PEP); their combination; or placebo (mainly oleic and linoleic acid) alone. Blood was drawn at baseline (N = 90) and endpoint (n = 65). Fatty acid levels were expressed as percent of total plasma fatty acids. Correlational and moderator/mediator analyses were done with SPSS Statistics 23. Results: At baseline: (1) DHA correlated negatively with alpha-linolenic acid (ALA) (r = -0.23, p = 0.029); (2) Arachidonic acid (AA, Ω6) correlated negatively with global functioning (r = -0.24, p = 0.022); (3) Total Ω3 correlated negatively with age (r = -0.22, p = 0.036) and diastolic blood pressure (r = -0.31, p = 0.006). Moderation: Baseline ALA moderated response to Ω3 supplementation: ALA levels above the sample mean (lower DHA) predicted significantly better placebo-controlled response (p = 0.04). Supplementation effects: Compared to placebo, 2 g Ω3 per day increased EPA blood levels sevenfold and DHA levels by half (both p < 0.001). Body weight correlated inversely with increased EPA (r = -0.52, p = 0.004) and DHA (r = -0.54, p = 0.003) and positively with clinical mood response. Mediation: EPA increase baseline-to-endpoint mediated placebo-controlled global function and depression improvement: The greater the EPA increase, the less the placebo-controlled Ω3 improvement. Conclusion: Ω3 supplementation at 2 g/day increases blood levels substantially, more so in smaller children. A possible U-shaped response curve should be explored.

KW - mediation

KW - moderation

KW - mood disorders

KW - omega-3 fatty acids

KW - plasma levels

KW - supplementation as treatment

UR - http://www.scopus.com/inward/record.url?scp=85018582542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018582542&partnerID=8YFLogxK

U2 - 10.1089/cap.2016.0123

DO - 10.1089/cap.2016.0123

M3 - Article

C2 - 28157380

AN - SCOPUS:85018582542

VL - 27

SP - 223

EP - 233

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 3

ER -